New hope for tough head and neck cancers: experimental combo trial launches
NCT ID NCT07136545
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new experimental drug called HCB101 combined with the immunotherapy pembrolizumab in 50 adults with head and neck cancer that has stopped responding to platinum chemotherapy. The goal is to see if the combination is safe and can shrink tumors. Participants receive weekly HCB101 infusions plus pembrolizumab every three weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HCB101 (an experimental drug) combined with pembrolizumab (an immunotherapy)
What this could lead to
If successful, this combination could offer a new treatment option for patients with head and neck cancer that has stopped responding to platinum chemotherapy.
What could go wrong
This is an early-phase trial with only 50 participants, so results may not apply broadly. The combination may cause significant side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang-Gung Memorial Hospital(Lin-Kou)
RECRUITINGTaoyuan, Guishan District, 333, Taiwan
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Taiwan University Hospital
RECRUITINGTaipei, Taipei city, 100, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Taipei Veterans General Hospital
RECRUITINGTaipei, taipei city, 112, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact